The Birth Control Market Is Broken.

The article investigates challenges facing contraceptive startups from investors and insurers. It attributes the problems of Evofem Biosciences, whose only product is the Phexxi contraceptive gel, to the broken U.S. health care system and the abandonment of women's health field by investors and pharmaceutical companies. It discusses roadblocks of health care economics including contraceptive approval from the U.S. Food and Drug Administration (FDA) and compliance with the Affordable Care Act.